Improvement in Quality of Life as a Predictor of Long-Term Remission in Crohn's Disease Patients Treated with Certolizumab Pegol

被引：0
|
作者：
Feagan, Brian [1 ]
Schreiber, Stefan [2 ]
Spearman, Marshall [3 ]
Kosutic, Gordana [4 ]
Hasan, Iram [3 ]
Coarse, Jason [4 ]
Sandborn, William [5 ,6 ]
机构：
[1] Robarts Res Inst, London, ON, Canada
[2] Univ Kiel, Kiel, Germany
[3] UCB Pharma, Smyrna, GA USA
[4] UCB Pharma, Raleigh, NC USA
[5] Univ Calif San Diego, La Jolla, CA 92093 USA
[6] UC San Diego Hlth Syst, La Jolla, CA USA
来源：
INFLAMMATORY BOWEL DISEASES | 2016年 / 22卷
关键词：
D O I：
10.1097/01.MIB.0000480351.31046.de
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P-100
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [1] Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol
    Melmed, Gil Y.
    McGovern, Dermot
    Schreiber, Stefan
    Kosutic, Gordana
    Spearman, Marshall
    Coarse, Jason
    Sandborn, William J.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (12) : 1937 - 1941
  • [2] Early Remission Status As a Predictor of Long-Term Outcome in Crohn's Disease Patients Treated With Certolizumab Pegol: Results of an Analysis From the PRECiSE 3 Study
    Melmed, Gil
    McGovern, Dermot
    Schreiber, Stefan
    Kosutic, Gordana
    Spearman, Marshall
    Coarse, Jason
    Sandborn, William
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S252 - S252
  • [3] Certolizumab pegol for induction of remission in Crohn's disease
    Yamazaki, Hajime
    So, Ryuhei
    Matsuoka, Katsuyoshi
    Kobayashi, Taku
    Shinzaki, Shinichiro
    Matsuura, Minoru
    Okabayashi, Shinji
    Kataoka, Yuki
    Tsujimoto, Yasushi
    Furukawa, Toshi A.
    Watanabe, Norio
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (08):
  • [4] Editorial: long-term safety and efficacy of certolizumab pegol for Crohn's disease
    Cesarini, M.
    Danese, S.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (10) : 1243 - 1243
  • [5] Predictors of Maintenance of Long-term Remission in Crohn's Disease Patients Treated With Certolizumab Pegol: Multivariate and Univariate Analyses From the PRECiSE 3 Study
    Sandborn, William
    Schreiber, Stefan
    Siegel, Corey
    Melmed, Gil
    McGovern, Dermot
    Pierre-Louis, Bosny
    Kosutic, Gordana
    Spearman, Marshall
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S514 - S514
  • [6] Patients With Crohn's Disease Treated With Certolizumab Pegol Experienced Long-Term Remission Regardless of Prior TNF-α Inhibitor Exposure (PRECiSE 4 Study)
    Sandborn, William J.
    Schreiber, Stefan
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Bloomfield, Ralph
    Lichtenstein, Gary
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S9 - S9
  • [7] CERTOLIZUMAB PEGOL IN PATIENTS WITH CROHN'S DISEASE: A LONG TERM UPDATE OF COMPASSIONATE USE
    Mocciaro, F.
    Renna, S.
    Orlando, A.
    Olivo, M.
    Sinagra, E.
    Cottone, M.
    [J]. DIGESTIVE AND LIVER DISEASE, 2011, 43 : S189 - S189
  • [8] Long-term remission with certolizumab pegol in Crohn's disease over 3.5 years: results from the PRECiSE 3 study
    Lichtenstein, G.
    Thomsen, O.
    Schreiber, S.
    Lawrance, I
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    [J]. INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S12 - S13
  • [9] Long-term Remission with Certolizumab Pegol in Crohn's Disease over 3.5 Years: Results from the PRECiSE 3 Study
    Lichtenstein, Gary
    Thomsen, Ole
    Schreiber, Stefan
    Lawrance, Ian
    Hanauer, Stephen
    Bloomfield, Ralph
    Sandborn, William
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S450 - S450
  • [10] Disease Activity as a Predictor of Long-Term Outcomes of Treatment With Certolizumab Pegol for Active Crohn's Disease: An Analysis of the PRECiSE 3 Study
    Choi, Jennifer
    Abraham, Bincy
    Wolf, Douglas
    Colombel, Jean-Frederic
    Kosutic, Gordana
    Spearman, Marshall
    Coarse, Jason
    Sandborn, William
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S509 - S510
12345